Massachusetts Society of Clinical Oncologists - FDA approves ramucirumab (Cyramza) plus erlotinib for first-line metastatic NSCLC

"The voice for cancer physicians and their patients in Massachusetts."

Home
For Professionals
FDA Approvals
FDA approves ramucirumab (Cyramza) plus erlotinib for first-line metastatic NSCLC

FDA approves ramucirumab (Cyramza) plus erlotinib for first-line metastatic NSCLC

02 Jun 2020 7:33 AM | Anonymous

The U.S. Food and Drug Administration approved ramucirumab (CYRAMZA, Eli Lilly and Company) in combination with erlotinib for first-line treatment of metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. Read full press release.

Massachusetts Society of Clinical Oncologists

P.O. Box 549154, Waltham, MA, 02454
Tel: 781.434.7329 | Fax: 781.464.4896 | email: msco@mms.org